Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Occupant Injury Severity in General Aviation Accidents Involving Excessive Landing Airspeed.

Boyd DD.

Aerosp Med Hum Perform. 2019 Apr 1;90(4):355-361. doi: 10.3357/AMHP.5249.2019.

PMID:
30922422
2.

A comparison of special category light-sport and corresponding type-certificated aircraft safety.

Anderson C, Stolzer A, Boyd DD.

J Safety Res. 2018 Sep;66:95-99. doi: 10.1016/j.jsr.2018.06.004. Epub 2018 Jun 14.

PMID:
30121116
3.

General Aviation Accidents Involving Octogenarian Airmen: Implications for Medical Evaluation.

Boyd DD.

Aerosp Med Hum Perform. 2018 Aug 1;89(8):687-692. doi: 10.3357/AMHP.5107.2018.

PMID:
30020052
4.

In-Flight Decision-Making by General Aviation Pilots Operating in Areas of Extreme Thunderstorms.

Boyd DD.

Aerosp Med Hum Perform. 2017 Dec 1;88(12):1066-1072. doi: 10.3357/AMHP.4932.2017.

PMID:
29157334
5.

A Review of General Aviation Safety (1984-2017).

Boyd DD.

Aerosp Med Hum Perform. 2017 Jul 1;88(7):657-664. doi: 10.3357/AMHP.4862.2017. Review.

PMID:
28641683
6.

Rates and causes of accidents for general aviation aircraft operating in a mountainous and high elevation terrain environment.

Aguiar M, Stolzer A, Boyd DD.

Accid Anal Prev. 2017 Oct;107:195-201. doi: 10.1016/j.aap.2017.03.017. Epub 2017 May 19.

PMID:
28532572
7.

General aviation accidents related to exceedance of airplane weight/center of gravity limits.

Boyd DD.

Accid Anal Prev. 2016 Jun;91:19-23. doi: 10.1016/j.aap.2016.02.019. Epub 2016 Mar 3.

PMID:
26945473
8.

Occupant Injury Severity and Accident Causes in Helicopter Emergency Medical Services (1983-2014).

Boyd DD, Macchiarella ND.

Aerosp Med Hum Perform. 2016 Jan;87(1):26-31. doi: 10.3357/AMHP.4446.2016.

PMID:
26735230
9.

Accident-precipitating factors for crashes in turbine-powered general aviation aircraft.

Boyd DD, Stolzer A.

Accid Anal Prev. 2016 Jan;86:209-16. doi: 10.1016/j.aap.2015.10.024. Epub 2015 Nov 17.

PMID:
26590507
10.

Should Charity Air Medical Organizations Require Commercial Certification of Their Pilots?

Boyd DD, Peters C.

Air Med J. 2015 Jul-Aug;34(4):188-94. doi: 10.1016/j.amj.2015.03.007.

PMID:
26206543
11.

Occupant injury and fatality in general aviation aircraft for which dynamic crash testing is certification-mandated.

Boyd DD.

Accid Anal Prev. 2015 Jun;79:182-9. doi: 10.1016/j.aap.2015.03.005. Epub 2015 Mar 30.

PMID:
25838192
12.

Causes and risk factors for fatal accidents in non-commercial twin engine piston general aviation aircraft.

Boyd DD.

Accid Anal Prev. 2015 Apr;77:113-9. doi: 10.1016/j.aap.2015.01.021. Epub 2015 Feb 18.

PMID:
25701648
13.

Causes of fatal accidents for instrument-certified and non-certified private pilots.

Shao BS, Guindani M, Boyd DD.

Accid Anal Prev. 2014 Nov;72:370-5. doi: 10.1016/j.aap.2014.07.013. Epub 2014 Aug 12.

PMID:
25118128
14.

Fatal accident rates for instrument-rated private pilots.

Shao BS, Guindani M, Boyd DD.

Aviat Space Environ Med. 2014 Jun;85(6):631-7.

PMID:
24919384
15.

ZKSCAN3 is a master transcriptional repressor of autophagy.

Chauhan S, Goodwin JG, Chauhan S, Manyam G, Wang J, Kamat AM, Boyd DD.

Mol Cell. 2013 Apr 11;50(1):16-28. doi: 10.1016/j.molcel.2013.01.024. Epub 2013 Feb 21.

16.

Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance.

Kim J, Ebertowski J, Janiga M, Arzola J, Gillespie G, Fountain M, Soderdahl D, Canby-Hagino E, Elsamanoudi S, Gurski J, Davis JW, Parker PA, Boyd DD.

BJU Int. 2013 May;111(6):934-40. doi: 10.1111/j.1464-410X.2012.11768.x. Epub 2013 Jan 25. Retraction in: BJU Int. 2014 Mar;113(3):509.

17.

Prostate cancer incidence in U.S. Air Force aviators compared with non-aviators.

Rogers D, Boyd DD, Fox EE, Cooper S, Goldhagen M, Shen Y, Del Junco DJ.

Aviat Space Environ Med. 2011 Nov;82(11):1067-70.

18.

Regulation of u-PAR gene expression by H2A.Z is modulated by the MEK-ERK/AP-1 pathway.

Chauhan S, Boyd DD.

Nucleic Acids Res. 2012 Jan;40(2):600-13. doi: 10.1093/nar/gkr725. Epub 2011 Sep 21.

19.

Increasing low risk prostate cancer incidence in United States Air Force servicemen and selection of treatments.

del Junco DJ, Fox EE, Cooper S, Goldhagen M, Koda E, Rogers D, Canby-Hagino E, Kim J, Pettaway C, Boyd DD.

J Urol. 2011 Jun;185(6):2137-42. doi: 10.1016/j.juro.2011.02.052. Epub 2011 Apr 15.

20.

Accelerated urokinase-receptor protein turnover triggered by interference with the addition of the glycolipid anchor.

Avila H, Wang H, Chauhan S, Hartig S, Boyd DD.

Biochem J. 2011 Mar 1;434(2):233-42. doi: 10.1042/BJ20101573.

PMID:
21143195
21.

MDM2 mediates ubiquitination and degradation of activating transcription factor 3.

Mo P, Wang H, Lu H, Boyd DD, Yan C.

J Biol Chem. 2010 Aug 27;285(35):26908-15. doi: 10.1074/jbc.M110.132597. Epub 2010 Jun 30.

22.

Gene trapping identifies chloride channel 4 as a novel inducer of colon cancer cell migration, invasion and metastases.

Ishiguro T, Avila H, Lin SY, Nakamura T, Yamamoto M, Boyd DD.

Br J Cancer. 2010 Feb 16;102(4):774-82. doi: 10.1038/sj.bjc.6605536. Epub 2010 Jan 19.

23.

Unbiased screening for transcriptional targets of ZKSCAN3 identifies integrin beta 4 and vascular endothelial growth factor as downstream targets.

Yang L, Zhang L, Wu Q, Boyd DD.

J Biol Chem. 2008 Dec 12;283(50):35295-304. doi: 10.1074/jbc.M806965200. Epub 2008 Oct 21.

24.

The previously undescribed ZKSCAN3 (ZNF306) is a novel "driver" of colorectal cancer progression.

Yang L, Hamilton SR, Sood A, Kuwai T, Ellis L, Sanguino A, Lopez-Berestein G, Boyd DD.

Cancer Res. 2008 Jun 1;68(11):4321-30. doi: 10.1158/0008-5472.CAN-08-0407.

25.

A novel high-throughput screening system identifies a small molecule repressive for matrix metalloproteinase-9 expression.

Nair RR, Avila H, Ma X, Wang Z, Lennartz M, Darnay BG, Boyd DD, Yan C.

Mol Pharmacol. 2008 Mar;73(3):919-29. Epub 2007 Dec 7.

PMID:
18065684
26.

A novel function of caspase-8 in the regulation of androgen-receptor-driven gene expression.

Qi W, Wu H, Yang L, Boyd DD, Wang Z.

EMBO J. 2007 Jan 10;26(1):65-75. Epub 2006 Dec 14.

27.

Regulation of matrix metalloproteinase gene expression.

Yan C, Boyd DD.

J Cell Physiol. 2007 Apr;211(1):19-26. Review.

PMID:
17167774
28.

Identification of an histone H3 acetylated/K4-methylated-bound intragenic enhancer regulatory for urokinase receptor expression.

Wang H, Yan C, Asangani I, Allgayer H, Boyd DD.

Oncogene. 2007 Mar 29;26(14):2058-70. Epub 2006 Sep 25.

PMID:
17001307
30.
31.

Expression cloning identifies transgelin (SM22) as a novel repressor of 92-kDa type IV collagenase (MMP-9) expression.

Nair RR, Solway J, Boyd DD.

J Biol Chem. 2006 Sep 8;281(36):26424-36. Epub 2006 Jul 10.

32.

ATF3 regulates the stability of p53: a link to cancer.

Yan C, Boyd DD.

Cell Cycle. 2006 May;5(9):926-9. Epub 2006 May 1.

PMID:
16628010
33.

Decoy molecules based on PNA-DNA chimeras and targeting Sp1 transcription factors inhibit the activity of urokinase-type plasminogen activator receptor (uPAR) promoter.

Borgatti M, Boyd DD, Lampronti I, Bianchi N, Fabbri E, Saviano M, Romanelli A, Pedone C, Gambari R.

Oncol Res. 2005;15(7-8):373-83.

PMID:
16491955
35.

Expression cloning of novel regulators of 92 kDa type IV collagenase expression.

Nair RR, Boyd DD.

Biochem Soc Trans. 2005 Nov;33(Pt 5):1135-6. Review.

PMID:
16246065
36.

Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.

Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, Ellis LM.

Cancer Res. 2005 Sep 1;65(17):7775-81.

37.

Prevalence of blood circulation misconceptions among prospective elementary teachers.

Pelaez NJ, Boyd DD, Rojas JB, Hoover MA.

Adv Physiol Educ. 2005 Sep;29(3):172-81.

38.

Activating transcription factor 3, a stress sensor, activates p53 by blocking its ubiquitination.

Yan C, Lu D, Hai T, Boyd DD.

EMBO J. 2005 Jul 6;24(13):2425-35. Epub 2005 Jun 2.

39.
40.

Inducible changes in cell size and attachment area due to expression of a mutant SWI/SNF chromatin remodeling enzyme.

Hill DA, Chiosea S, Jamaluddin S, Roy K, Fischer AH, Boyd DD, Nickerson JA, Imbalzano AN.

J Cell Sci. 2004 Nov 15;117(Pt 24):5847-54.

41.

Involvement of heparanase in tumor metastases: a new target in cancer therapy?

Boyd DD, Nakajima M.

J Natl Cancer Inst. 2004 Aug 18;96(16):1194-5. No abstract available.

PMID:
15316047
42.
44.

Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness.

Boyd DD, Wang H, Avila H, Parikh NU, Kessler H, Magdolen V, Gallick GE.

Clin Cancer Res. 2004 Feb 15;10(4):1545-55.

46.

Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers.

Schewe DM, Leupold JH, Boyd DD, Lengyel ER, Wang H, Gruetzner KU, Schildberg FW, Jauch KW, Allgayer H.

Clin Cancer Res. 2003 Jun;9(6):2267-76.

47.
49.
50.

Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis.

Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE.

Cancer. 2002 Jan 15;94(2):344-51.

Supplemental Content

Support Center